Pfizer’s SARS-CoV-2 vaccine doesn’t have an effect on the honeymoon section of kind 1 diabetes

In a current examine printed in Vaccines, researchers reported that Pfizer’s BNT162b2 vaccine in opposition to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) doesn’t have an effect on the honeymoon section of kind 1 diabetes (T1D).

Study: BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Image Credit: Maria Kaminska/Shutterstock
Examine: BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Picture Credit score: Maria Kaminska/Shutterstock

Diabetes has been thought of a danger issue for coronavirus illness 2019 (COVID-19) morbidity and mortality. Though present COVID-19 vaccines have considerably lowered morbidity and mortality, quite a few reviews of vaccination-induced hyperglycemia (ViHG) and different related issues have surfaced.

Numerous research have reported that some T1D sufferers expertise a transient instability of blood glucose ranges following COVID-19 vaccination, which resolves in just a few days. Nevertheless, the influence of SARS-CoV-2 vaccination on the medical remission section of T1D, generally known as the honeymoon section, stays unclear.

The examine and findings

Within the current examine, researchers described the case of a T1D affected person who obtained the BNT162b2 vaccine throughout the honeymoon section. The topic was a 24-year-old Italian man recognized with T1D in July 2020 after extreme hyperglycemia with average diabetic ketoacidosis (DKA) requiring hospitalization.

The affected person was initially handled with intravenous insulin and subcutaneous insulin after DKA decision. A vitamin specialist prescribed a Mediterranean weight loss plan (1.8-kilo energy/day). The affected person was discharged after 5 days of admission. The entire every day insulin dose was lowered progressively at outpatient follow-up visits as a consequence of frequent fasting and postprandial hypoglycemic episodes.

Low-dose basal insulin was maintained after 30 days. The topic underwent a combined meal tolerance check (MMTT) two months after DKA onset and hyperglycemia decision. The fasting connecting peptide (C-peptide) worth was 0.74 ng/ml, and the height worth was 2.95 ng/ml. The affected person already transitioned to the honeymoon section, indicated by an insulin dose-adjusted hemoglobin A1c (IDAA1c) [a marker for clinical remission of T1D] worth of 5.66.

Laboratory assessments corresponding to full blood depend, lipid profile, markers of liver, thyroid, and kidney perform markers, and people of celiac illness and thyroid autoimmunity had been unremarkable. Fourteen months after T1D analysis, throughout a follow-up MMTT, the topic confirmed preserved residual beta-cell perform.

The case was nonetheless on a low insulin dosage. The topic obtained the primary BNT162b2 vaccine on December 13, 2021, and the second on January 3, 2022. After the primary dose, the affected person skilled deteriorating glucose management; that’s, the frequency of postprandial hyperglycemic episodes elevated reasonably, and this development was notably aggravated after the second vaccination. This prompted the resumption of mealtime insulin injections for every week.

Ambulatory glucose profile was obtained from subcutaneous glucose sensor at 1) 21 days pre-first vaccination, 2) 21 days post-first dose, 3) 21 days post-second dose, and 4) 42 days post-second vaccination. The authors famous that glucose management deterioration ensued from vaccination, notably extra evident after administering the second dose.

No vital episodes of hypoglycemia had been noticed throughout the follow-up visits, and no opposed occasions occurred after the primary or second vaccination. Throughout an MMTT three months after the second vaccination, that’s, 19 months post-T1D onset, the authors unexpectedly noticed that the affected person was nonetheless within the honeymoon section. This was confirmed by an IDAA1c worth of 6.1. There have been no substantial modifications within the residual endogenous insulin secretion or every day insulin necessities.

Chemiluminescent microparticle immunoassay was carried out three months post-administration of the second dose. It revealed the presence of excessive anti-SARS-CoV-2 neutralizing immunoglobulin G (IgG) antibody titers and the absence of neutralizing IgM antibodies, indicating that the humoral antibody response in opposition to SARS-CoV-2 was strong following a two-dose routine.


The authors reported that vaccination with two doses of the BNT162b2 vaccine doesn’t negatively influence the honeymoon section or the perform of residual beta cells. Vaccination triggered solely a short lived ViHG with out considerably influencing the course of the honeymoon section. The vaccine didn’t set off or exacerbate islet autoimmunity. These outcomes could encourage SARS-CoV-2 vaccination amongst T1D sufferers throughout their honeymoon section and assist overcome the vaccine skepticism noticed in lots of such sufferers.

However, it’s vital to delineate in massive potential research the immunometabolic influence and security of the vaccine in T1D sufferers throughout the honeymoon section. The researchers instructed that T1D sufferers ought to be appropriately recommended about the potential of transient ViHG and strictly surveilled post-vaccination throughout outpatient visits.

Journal reference:



Leave a Reply